ibd
Lihi Godny, from Rabin Medical Center in Israel, talks about the next steps research has to focus in to improve the FMT efficacy for IBD patients.
Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, talks about the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.
The findings of a new study suggest that the new nanomedicine approach can improve the delivery of TNF-α-siRNA in people with IBD.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
Specific gut bacteria may drive some autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. A new study published in Cell Host & Microbe claims.
Researchers have found that disrupting the microbiota-gut axis by altering circadian rhythms or diet can drive Crohn-like inflammation of the intestine in mice.
Researchers have found a class of metabolites that can shift the gut microbiota towards an IBD-like composition.
IBD: a study, published in Nature, for the first time analyzed the chemical and molecular events that disrupt the gut microbiota during flare-ups.
Researchers at the University of Michigan developed a mouse model that recapitulates many hallmarks of gut inflammation seen in people with Crohn’s disease.
